The lymphocyte differentiation antigen CD4 serves as a receptor for human retroviruses associated with acquired immunodeficiency syndrome (AIDS) through its interaction with the major envelope virion glycoprotein, gpl20, which is also expressed on the surface of infected cells. In these experiments, purified gpl20 was shown to bind to normal human T-lymphocyte populations. The gpl2O-CD4 complex served as a target antigen for antibody-dependent complementmediated cytolysis by a goat serum raised against native gpl20. However, patient sera that bound to gpl20-adsorbed cells failed to direct their destruction in the presence of complement. In contrast, these sera were potent mediators of antibodydependent cellular cytotoxicity. These studies demonstrate that gpl20 situated on the cell surface can serve as an effective target for immune destruction by patient antibodies and effector lymphocytes. The possible contribution of this type of immunity to control of disease progression, on the one hand, and to lymphocyte destruction and immunopathology observed in AIDS, on the other, is discussed.
The most profound hematologic feature associated with acquired immunodeficiency syndrome (AIDS) is the functional impairment and quantitative depletion of the subset of lymphocytes that express the CD4 surface antigen (1) (2) (3) (4) (5) (6) . Infection of CD4 cells in vitro results in the rapid spread of virus throughout the culture and subsequent cell death due to the as yet undefined process of virus-induced cytopathology (7) (8) (9) (10) (11) (12) . This rapid in vitro lympholysis is not, however, representative ofthe clinical disease state. Evidence suggests that fulminant viremia accompanied by large scale infection of CD4-positive lymphocytes does not occur at any stage of disease. Harper et al. (13) reported that by in situ hybridization analysis the number of infected cells expressing viral RNA in either peripheral blood or lymph nodes remained well below 0.01% in both early and late stages of AIDS. While it is likely that more cells are infected than are actively expressing viral information, the degree of lymphocyte depletion does not appear to be solely due to infectious virus spread but may involve other processes not directly linked to virus infection.
The current body of evidence suggests that the T-cell lymphotropic properties of the causative agent virus are due, in large part, to the interaction between the major virion envelope glycoprotein (gp120) and specific epitopes of the CD4 antigen complex. Monoclonal antibodies directed against particular determinants of CD4 have been shown to block both infection (14, 15) and multinucleated giant cell formation (16) , in addition to precipitating gpl2O-CD4 complexes from infected cells (17) . Recent studies revealed that purified gpl20 can effectively block cell fusion, most likely by competing for available CD4 sites on noninfected cells (18) . In addition, purified gpl20 readily associates with the CD4 molecules and forms a stable complex on the cell surface (19) . This latter finding suggested the possibility that free gpl20 bound to noninfected CD4-expressing lymphocytes could serve as a potential target for immune attack resulting in subsequent lympholysis.
MATERIALS AND METHODS
Cells. Normal CD4-positive lymphocyte populations (CD4 cells) were obtained by stimulating normal donor peripheral blood mononuclear cells with tetanus toxoid for 5 days, sorting for CD4 expression, and expanding in the presence of recombinant interleukin 2. CEM cell lines (CEM) or human T-cell lymphotropic virus IIIB (HTLV-IIIB)t chronically infected CEM (CEM/IIIB) have been described (19) . gpl20 and Goat gpl2O Antisera. The gp120 was isolated from HTLV-IIIn-infected H9 cells as described (18) . Briefly, cells were lysed with 0.5% Triton X-100, and the soluble fraction was initially passed over an affinity resin containing human high-titered antibodies followed by lentil lectin chromatography. Details of the generation of goat antiserum to gp120 have been recently reported (20) . Monoclonal antibody to HTLV-IIIB gpl20 was the generous gift of Robert Ting (Biotech) .
Adsorption of gp120 to Noninfected Cells. Four million noninfected CD4 cells or CEM cells were placed in duplicate tubes containing 1 
RESULTS
Binding of Various Antibodies to gp120 Associated with the Cell Surface. The availability of human lymphocytes exhibiting a single viral antigen at the cell surface would greatly facilitate determining the role of viral products as a target for immune attack. Initial studies were thus undertaken to determine the binding characteristics of gp120 to normal CD4-positive lymphocyte populations (CD4 cells). These CD4 cells Were incubated with purified gpl20 isolated from HTLV-IIIB-infected cells and subsequently assessed for ligand binding by cytofluorographic analysis. Using a monoclonal antibody against gp120, goat anti-gpl20 serum, and patient serum, the binding of free glycoprotein to the surface of CD4-expressing lymphocytes was readily apparent with specific staining of >90% of cells (Fig. 1 E-J) . The gpl20 bound to and blocked the OKT4A-defined epitope of CD4 ( Fig. 1 C and D (Fig. 1 A and B) was unaffected by gpl20 binding, indicating the specificity of binding to a subregion of the CD4 molecule.
Since the orientation and expression of gpl20 bound to noninfected lymphocytes may be different than that expressed on either virions or virus-infected cells, the ability of the anti-gpl20 antisera to bind to infected cells and gpl20-adsorbed cells was also examined. The lack of chronically infected CD4-positive lymphocyte cell populations necessitated the use of CEM and chronically infected CEM (CEM/IIIB) cell lines for this analysis (19) . Cytofluorography revealed that all of the antibodies tested bound the virusinfected cells (Fig. 2 B, E , and H) in a manner similar to the gpl20-adsorbed CD4 cells (Fig. 2 C, F, and I) . However, mean fluorescence was higher in gpI20-adsorbed CD4 cells, suggesting that antigen density was greater. The high-titered goat anti-gpl20 antisera bound in a pattern similar to the nionoclonal anti-gpl20.
ACC. The extensive reactivity of these antibodies with the gpl20 expressed by infected cells or adsorbed onto cells led to an investigation of their ability to mediate cellular destruction. Initially, ACC was evaluated. As shown in Table 1 , ACC goat anti-gpl20 antiserum specifically lysed the gp120-adsorbed cells, with maximal lysis of49.5% at a 1:20 dilution. Furthermore, goat anti-gpl20 antiserum also lysed infected cells (not shown). In contrast, randomly chosen patient sera failed to produce significant lysis over control values, even though these sera readily bound to the surface of the gpl20-adsorbed target cells (Fig. 1J) . Repeat experiments using different complement sources (i.e., guinea pig, baby rabbit, and human) failed to reveal direct cytolytic activity with patient sera (data not shown), in agreement with studies using virus-infected target cells (22) .
ADCC. Our previous work in murine retrovirus tumor systems had highlighted ADCC as an effective means of target-cell destruction, both in vitro and in vivo, which could occur even with antibodies that wer6 relatively ineffective in ACC (23) (24) (25) (26) (27) . Therefore, the ability of patient sera to participate in ADCC was investigated. The results (Table 1, ADCC) demonstrate that all patient sera tested were capable of directing ADCC activity against the gpl20-adsorbed target cells. The adsorption of gpl20 onto CD4-positive cells consistently increases their lytic susceptibility 8-to 10-fold in the presence of patient antibodies and normal effector cells. Antibody titrations consistently revealed that maximal ADCC was apparent only at high dilutions of patient sera (1:102 to 1:104). The inability of the goat serum to mediate ADCC may reflect the inefficient binding of goat IgG by human Fc receptor-bearing cells.
The CEM and chronically infected CEM cell lines were again used to determine the role of ADCC against infected cells. As shown in Fig. 3 , patient sera failed to lyse noninfected CEM cells in the presence of normal donor lymphocytes. In contrast, CEM/IIIB were specifically lysed by patient sera in the presence of normal donor lymphocytes.
A direct comparison of ADCC against CEM/IUIB and CEM with gpl20 adsorbed on the surface revealed distinctive features (Fig. 4) . First, the lysis of gpl20-adsorbed cells was consistently greater than that of chronically infected CEM with serum from patient 1 as well as other patient sera tested (not shown). Second, whereas maximum lysis of CEM/IIIB cells always occurred at the highest concentration of patient sera, peak lysis of gpl20-adsorbed targets was consistently preceded by a "prozone" of suboptimal lysis. Most sera had a peak lysis of gpl20-adsorbed cells at dilutions of 1:102 to 1:104. Differences between lysis of infected and gpl20-adsorbed cells may be due to either qualitative or quantitative expression of gpl20. Moreover, the exposed epitopes of gpl20 on adsorbed cells may not be expressed to the same 
DISCUSSION
Antibodies in patients directed against gpl20 have already been shown to exhibit virus-neutralizing activities (20) and may, therefore, be involved in preventing further spread of the virus. The finding that patient sera can direct the cell-mediated destruction of gpl20-bearing cells indicates the presence of an additional barrier to HIV infection and disease progression. Generation of antibodies mediating ADCC following viral infection could lead to the elimination of infected cells expressing viral proteins on their surface. Moreover, if disease transmission involves not only free virus but also transfer of infected cells, pre-existing antibodies mediating cell lysis may thus be critical. The amount of antibody required to mediate ADCC is small. In a recently completed survey of 75 seropositive patients, we found that peak lytic activity was most frequently observed with serum dilutions in the range 1:102 to 1:104 (data not shown). Furthermore, ADCC mediated by patient sera appears to be broadly reactive, effectively directing the lysis of cells expressing gp120 from widely divergent HIV isolates (H.K.L., unpublished observation). These findings, in addition to a recent report demonstrating the absence of complement-dependent lytic activity against infected cells by patient sera (22) , indicate that ADCC may assume an increasingly important (28) suggested that HIV p24 may be a target for antibodies directing ADCC based on a correlation between the disappearance of anti-p24 antibodies and ADCC activity. Although in our present study gp120 is clearly an ADCC target, we have little direct evidence of a similar role for p24. Cytofluorometric analysis of infected cells using high titered monospecific anti-p24 sera revealed very low levels ofcell surface p24. Furthermore, our preliminary results indicate that a number of sera devoid of anti-p24 activity by immunoblot can still direct ADCC (H.K.L., unpublished data). In contrast, we have been unable to demonstrate ADCC using sera devoid of gpl20 ME 30-antibodies. Taken together these results suggest that the role of p24 as a target antigen for ADCC is, at best, unclear.
Quite separate from the possible clinical significance of the present findings, the adsorption of purified gp120 to normal lymphocytes provides an important investigative tool since it allows one to define the specificity of an immune response by individualizing the target antigen. Specific cellular anti-viral immunity appears to exist in infected individuals when tested against autologous CD4 cells with adsorbed gpl20 (K.J.W., H.K.L., T.J.M., P. M. Ahearne, K. C. Stine, D. T. Durach & D.P.B., unpublished data). This approach lends itselfto the analysis of various arms of the cellular compartment of the immune system as to how each responds to the infecting agent.
